Home Capital Results

iX Biopharma sinks deeper into the red in 1Q on higher expenses

Stanislaus Jude Chan
Stanislaus Jude Chan11/8/2017 07:28 PM GMT+08  • 2 min read
iX Biopharma sinks deeper into the red in 1Q on higher expenses
SINGAPORE (Nov 8): Specialty pharmaceutical firm iX Biopharma saw its net losses quadruple to $3.2 million for the 1Q18 ended September, widening from a net loss of $0.8 million a year ago.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (Nov 8): Specialty pharmaceutical firm iX Biopharma saw its net losses quadruple to $3.2 million for the 1Q18 ended September, widening from a net loss of $0.8 million a year ago.

Revenue rose 14% to $1.7 million in 1Q18, from $1.5 million a year ago.

This was mainly due to an increase in laboratory testing services as well as the strengthening of the Australian dollar.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.